There are five types of leukemia:
acute lymphoid leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), hairy cell leukemia, and chronic myeloid leukemia (CML).
Acute lymphoid leukemia is highly proliferative in nature.
- Chimeric Antigen Receptor - Modified T Cells for
Acute Lymphoid Leukemia; Stephan A. Grupp MD, PhD, University of Pennsylvania Children's Hospital of Philadelphia.
Not exact matches
The novel tryptamine derivative JNJ - 26854165 induces wild - type p53 - and E2F1 - mediated apoptosis in
acute myeloid and
lymphoid leukemias.
This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates
lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes
acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.
These data indicate that the JAK2V617F allele is present in
acute and chronic myeloid malignancies but not in
lymphoid malignancies.
Leukemia can be
acute (rapidly progressing) or chronic (slow growing),
lymphoid or myeloid.